查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球子宫内膜异位症药物市场 2017-2027：子宫内膜异位症类型,诊断法,治疗法,药物类别,诊断类型,分销渠道,用户,行业规模,份额,趋势,地区机会/预测
市场调查报告书
商品编码
1152247

全球子宫内膜异位症药物市场 2017-2027：子宫内膜异位症类型,诊断法,治疗法,药物类别,诊断类型,分销渠道,用户,行业规模,份额,趋势,地区机会/预测

Endometriosis Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, & Forecast, 2017-2027 Segmented By Endometriosis Type, Diagnostic Method, Treatment Method, Drug Category, Diagnostics Type, Distribution Channel, End-User, Region
出版日期: | 出版商: TechSci Research | 英文 111 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球子宫内膜异位症药物市场预计到 2027 年将显着增长。

妇科和慢性疾病的蔓延、子宫内膜异位症患者人数增加、先进子宫内膜异位症治疗的研发活动增加以及对激素疗法和新药的需求增加等因素正在推动我们的增长这个市场。

在这份报告中，我们调查了全球子宫内膜异位症药物市场，提供了市场概况、市场规模和市场份额的趋势和预测，按细分市场/地区/主要国家进行了详细分析，总结了影响因素的分析，竞争环境、主要公司概况等。

内容

第 1 章产品概述

第二章研究方法论

第 3 章 COVID-19 对全球子宫内膜异位症药物市场的影响

第 4 章 VOC（客户之声）

第 5 章执行摘要

第6章临床试验分析

第7章全球子宫内膜异位症药物市场展望

  • 市场规模和预测
  • 市场份额/预测
    • 按子宫内膜异位症的类型分类（浅表腹膜病变、子宫内膜异位症、深部浸润性子宫内膜异位症）
    • 通过诊断方法（超声波、盆腔检查、腹腔镜检查、MRI 等）
    • 按治疗方法（激素疗法/疼痛管理）
    • 按分销渠道（零售药店、医院药店、在线药店）
    • 按最终用户（医院和诊所、门诊护理中心等）
    • 按地区
    • 按公司
  • 产品市场地图

第八章北美子宫内膜异位症药物市场展望

  • 市场规模和预测
  • 市场份额/预测
    • 按子宫内膜异位症类型
    • 通过诊断方法
    • 按治疗方法
    • 按分销渠道
    • 最终用户
    • 按国家
  • 国家分析

第 9 章：欧洲子宫内膜异位症药物市场展望

  • 市场规模和预测
  • 市场份额/预测
    • 按子宫内膜异位症类型
    • 通过诊断方法
    • 按治疗方法
    • 按分销渠道
    • 最终用户
    • 按国家
  • 国家分析

第 10 章亚太地区子宫内膜异位症药物市场展望

  • 市场规模和预测
  • 市场份额/预测
    • 按子宫内膜异位症类型
    • 通过诊断方法
    • 按治疗方法
    • 按分销渠道
    • 最终用户
    • 按国家
  • 国家分析

第11章南美子宫内膜异位症药物市场展望

  • 市场规模和预测
  • 市场份额/预测
    • 按子宫内膜异位症类型
    • 通过诊断方法
    • 按治疗方法
    • 按分销渠道
    • 最终用户
    • 按国家
  • 国家分析

第 12 章中东和非洲子宫内膜异位症市场展望

  • 市场规模和预测
  • 市场份额/预测
    • 按子宫内膜异位症类型
    • 通过诊断方法
    • 按治疗方法
    • 按分销渠道
    • 最终用户
    • 按国家
  • 国家分析

第 13 章市场动态

  • 司机
  • 任务

第十四章市场趋势与市场发展

第15章竞争格局

  • Abbott Laboratories, Inc.
  • AbbVie, Inc.
  • Bayer AG
  • Pfizer, Inc.
  • Ipsen SA
  • Evotec SE
  • Myovant Sciences Ltd.
  • Philogen S.p.A.
  • Astellas Pharma Inc.
  • Orphagen Pharmaceuticals, Inc.

第16章 策略建议

简介目录
Product Code: 12975

The global endometriosis therapeutics market is expected to increase appreciably through 2027. Endometriosis is a disorder characterized by the tissues like the covering of the uterus growing on the outer part of the uterus. It is a type of chronic disease led to serve life-impacting pains during periods, sexual intercourse, urination, chronic pelvic pain, abdominal bloating, nausea, and fatigue. Sometimes extreme levels of these disorders can result in depression, anxiety, and infertility. Across the globe, various initiatives are going to make people, majorly women, aware of the problem; there are many off-label practices due to lack of information. In developing countries, the cost of therapy is creating restrain in growth.

According to WHO, almost 10% of reproductive-age women will be affected by this syndrome or disease globally in 2021. Different government organizations and NGOs are running global campaigns to create Awareness. Launching new advanced products and therapies, Awareness about continuous improvement in patients, and improvement in non-invasive diagnostic methods are one of the major factors responsible for the market. Thus, we can expect a rise in growth and demand in the market share of Endometriosis therapeutics in 2027.

Growing Awareness About the Disease and Treatment in Society

The increasing pervasiveness of gynecological and chronic diseases, an increasing number of people suffering from endometriosis, ongoing R&D activities for advanced endometriosis treatment, and rising demand for hormonal therapies & novel drugs are factors responsible for the growth of the Endometriosis Therapeutics Market. As the population increases, the demand for medical treatment and equipment is increasing in various parts of the world. According to the WHO report, in 2021, almost 190 million reproductive women and girls will be affected by endometriosis worldwide. The above data shows that there is massive potential in the market as the number of potential customers is in the millions and continues its grow as the population increases in developing countries; patients are still not aware of endometriosis and take the wrong drugs and treatment when there are any health problems. Thus, different initiatives and awareness program are going on through social media, Online platforms, newspapers, and other means. Therefore, growing awareness about endometriosis can positively impact the market share.

The large number of women worldwide suffering from endometriosis led to increased demand for treatment. Due to its positive outcome, patients are suggesting the treatment to another patient, and this word of mouth are most impactful in term of awareness. Hence, this factor can positively impact the market share. These increasing demands make the player work for significant technological Advancement in therapeutics and improving treatment. Technological Advancement in segments helps the doctor to treat the patient with minimal surgical cuts on the body, less painful processes, and shorter recovery time. All these efforts make the method more in demand and market share.

Various community, government, and community initiatives are running to uplift women's health. Australia has funded 58 million for improving endometriosis under the national action plan. Janani Shishu Suraksha Yojana, National action plan, Women's health alliance is an example of global initiatives. These policies led to increasing demand for endometriosis therapeutics in the market. All the factors mentioned above are expected to drive the growth of the Endometriosis Therapeutics Market.

Off-Label Medication Practices are Hurdle in Growth

After so many awareness campaigns are running over the world, many people are still not reachable. Forget about the treatment. They are unaware of endometriosis and take treatment for another problem. Apart from this, in poorer countries, therapy costs are costly that restrain the market growth.

Continuous R&D for Advance Drug Technology is Driving Growth

The evolution of methods and drugs due to technological advancement per market requirements is expected to create impressive growth in the Endometriosis Therapeutics Market. Market players are proposing novel transdermal drug delivery technologies such as topical applicators to overcome the side effects of oral contraceptives and improve efficiency as many women sufferings from endometriosis increase the demand for treatment.

In 2022, Myovant science Limited and Pfizer LLC. Is collaborate and continued to jointly commercialize MYFEMBREE. This medicine is expected to help both companies combine their expertise to deliver the drug quickly and gain market size.

In 2022, Astellas Pharma Inc. announced the outcome of the drug, which is clinical trial version Phase 3, "SKYLIGHT 4". It is a non-hormonal composite studied for treating sensible to severe vasomotor symptoms associated with menopause (VMS) which will encourage future regulatory organizing submissions.

Market Segmentation

The global endometriosis therapeutics market is segmented based on endometriosis type, diagnostic method, therapeutic method, distribution channel, and end user type. Based on endometriosis type, market is divided into superficial peritoneal lesion, endometrioma, deeply infiltrating endometriosis therapeutics. Based on diagnostic method, market is divided into ultrasound, pelvic examination, laparoscopy, magnetic resonance imaging, and others. Based on treatment method, market is split into hormonal therapy, and pain management. Based on drug category, market is divided into oral contraceptives, progestins, NSAIDs, GnRH analogues, and others. Based on diagnostics type, market is split into pure medical imaging v/s general laboratory use. Based on distribution channel, market is divided into retail pharmacies, hospital pharmacies, online pharmacies. Based on end user, market is divided into hospitals & clinics, ambulatory care center, and others, by company.

Market Players

The Abbott Laboratories, Inc. ; AbbVie, Inc.; Bayer AG; Pfizer, Inc.; Ipsen SA; Evotec SE; Myovant Sciences Ltd.; Philogen S.p.A.; Astellas Pharma Inc.; Orphagen Pharmaceuticals, Inc. are the major market player operating in the Endometriosis Therapeutics Market.

Report Scope:

In this report, global Endometriosis Therapeutics Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Endometriosis Therapeutics Market, by endometriosis type:

  • Superficial Peritoneal Lesion
  • Endometrioma
  • Deeply Infiltrating Endometriosis Therapeutics

Endometriosis Therapeutics Market, by diagnostic method:

  • Ultrasound
  • Pelvic Examination
  • Laparoscopy
  • Magnetic Resonance Imaging
  • Others

Endometriosis Therapeutics Market, by treatment method:

  • Hormonal Therapy
  • Pain Management

Endometriosis Therapeutics, by drug category:

  • Oral Contraceptives
  • Progestins
  • NSAIDs
  • GnRH Analogues
  • Others

Endometriosis Therapeutics, by distribution channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Endometriosis Therapeutics Market, by end user type:

  • Hospitals & Clinics
  • Ambulatory Care Center
  • Others

Medical market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Endometriosis Therapeutics Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Endometriosis Therapeutics Market

4. Voice of Customer

5. Executive Summary

6. Clinical Trial Analysis

7. Global Endometriosis Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
    • 7.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
    • 7.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
      • 7.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
    • 7.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 7.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 7.2.6. By Region
    • 7.2.7. By Company (2021)
  • 7.3. Product Market Map

8. North America Endometriosis Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
    • 8.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
    • 8.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
      • 8.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
    • 8.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 8.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 8.2.6. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Endometriosis Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Endometriosis Type
        • 8.3.1.2.2. By Diagnostic Method
        • 8.3.1.2.3. By Therapeutic Method
        • 8.3.1.2.4. By Distribution Channel
        • 8.3.1.2.5. By End User
    • 8.3.2. Mexico Endometriosis Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Endometriosis Type
        • 8.3.2.2.2. By Diagnostic Method
        • 8.3.2.2.3. By Therapeutic Method
        • 8.3.2.2.4. By Distribution Channel
        • 8.3.2.2.5. By End User
    • 8.3.3. Canada Endometriosis Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Endometriosis Type
        • 8.3.3.2.2. By Diagnostic Method
        • 8.3.3.2.3. By Therapeutic Method
        • 8.3.3.2.4. By Distribution Channel
        • 8.3.3.2.5. By End User

9. Europe Endometriosis Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
    • 9.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
    • 9.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
      • 9.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
    • 9.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 9.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 9.2.6. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. France Endometriosis Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Endometriosis Type
        • 9.3.1.2.2. By Diagnostic Method
        • 9.3.1.2.3. By Therapeutic Method
        • 9.3.1.2.4. By Distribution Channel
        • 9.3.1.2.5. By End User
    • 9.3.2. United Kingdom Endometriosis Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Endometriosis Type
        • 9.3.2.2.2. By Diagnostic Method
        • 9.3.2.2.3. By Therapeutic Method
        • 9.3.2.2.4. By Distribution Channel
        • 9.3.2.2.5. By End User
    • 9.3.3. Italy Endometriosis Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Endometriosis Type
        • 9.3.3.2.2. By Diagnostic Method
        • 9.3.3.2.3. By Therapeutic Method
        • 9.3.3.2.4. By Distribution Channel
        • 9.3.3.2.5. By End User
    • 9.3.4. Germany Endometriosis Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Endometriosis Type
        • 9.3.4.2.2. By Diagnostic Method
        • 9.3.4.2.3. By Therapeutic Method
        • 9.3.4.2.4. By Distribution Channel
        • 9.3.4.2.5. By End User
    • 9.3.5. Spain Endometriosis Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Endometriosis Type
        • 9.3.5.2.2. By Diagnostic Method
        • 9.3.5.2.3. By Therapeutic Method
        • 9.3.5.2.4. By Distribution Channel
        • 9.3.5.2.5. By End User

10. Asia-Pacific Endometriosis Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
    • 10.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
    • 10.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
      • 10.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
    • 10.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 10.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 10.2.6. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Endometriosis Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Endometriosis Type
        • 10.3.1.2.2. By Diagnostic Method
        • 10.3.1.2.3. By Therapeutic Method
        • 10.3.1.2.4. By Distribution Channel
        • 10.3.1.2.5. By End User
    • 10.3.2. India Endometriosis Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Endometriosis Type
        • 10.3.2.2.2. By Diagnostic Method
        • 10.3.2.2.3. By Therapeutic Method
        • 10.3.2.2.4. By Distribution Channel
        • 10.3.2.2.5. By End User
    • 10.3.3. Japan Endometriosis Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Endometriosis Type
        • 10.3.3.2.2. By Diagnostic Method
        • 10.3.3.2.3. By Therapeutic Method
        • 10.3.3.2.4. By Distribution Channel
        • 10.3.3.2.5. By End User
    • 10.3.4. South Korea Endometriosis Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Endometriosis Type
        • 10.3.4.2.2. By Diagnostic Method
        • 10.3.4.2.3. By Therapeutic Method
        • 10.3.4.2.4. By Distribution Channel
        • 10.3.4.2.5. By End User
    • 10.3.5. Australia Endometriosis Therapeutics Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Endometriosis Type
        • 10.3.5.2.2. By Diagnostic Method
        • 10.3.5.2.3. By Therapeutic Method
        • 10.3.5.2.4. By Distribution Channel
        • 10.3.5.2.5. By End User

11. South America Endometriosis Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
    • 11.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
    • 11.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
      • 11.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
    • 11.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 11.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 11.2.6. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Endometriosis Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Endometriosis Type
        • 11.3.1.2.2. By Diagnostic Method
        • 11.3.1.2.3. By Therapeutic Method
        • 11.3.1.2.4. By Distribution Channel
        • 11.3.1.2.5. By End User
    • 11.3.2. Argentina Endometriosis Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Endometriosis Type
        • 11.3.2.2.2. By Diagnostic Method
        • 11.3.2.2.3. By Therapeutic Method
        • 11.3.2.2.4. By Distribution Channel
        • 11.3.2.2.5. By End User
    • 11.3.3. Colombia Endometriosis Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Endometriosis Type
        • 11.3.3.2.2. By Diagnostic Method
        • 11.3.3.2.3. By Therapeutic Method
        • 11.3.3.2.4. By Distribution Channel
        • 11.3.3.2.5. By End User

12. Middle East and Africa Endometriosis Therapeutics Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
    • 12.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
    • 12.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
      • 12.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
    • 12.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 12.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 12.2.6. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Endometriosis Therapeutics Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Endometriosis Type
        • 12.3.1.2.2. By Diagnostic Method
        • 12.3.1.2.3. By Therapeutic Method
        • 12.3.1.2.4. By Distribution Channel
        • 12.3.1.2.5. By End User
    • 12.3.2. UAE Endometriosis Therapeutics Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Endometriosis Type
        • 12.3.2.2.2. By Diagnostic Method
        • 12.3.2.2.3. By Therapeutic Method
        • 12.3.2.2.4. By Distribution Channel
        • 12.3.2.2.5. By End User
    • 12.3.3. Saudi Arabia Endometriosis Therapeutics Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Endometriosis Type
        • 12.3.3.2.2. By Diagnostic Method
        • 12.3.3.2.3. By Therapeutic Method
        • 12.3.3.2.4. By Distribution Channel
        • 12.3.3.2.5. By End User
    • 12.3.4. Egypt Endometriosis Therapeutics Market Outlook
      • 12.3.4.1. Market Size & Forecast
        • 12.3.4.1.1. By Value
      • 12.3.4.2. Market Share & Forecast
        • 12.3.4.2.1. By Endometriosis Type
        • 12.3.4.2.2. By Diagnostic Method
        • 12.3.4.2.3. By Therapeutic Method
        • 12.3.4.2.4. By Distribution Channel
        • 12.3.4.2.5. By End User
    • 12.3.5. Turkey Endometriosis Therapeutics Market Outlook
      • 12.3.5.1. Market Size & Forecast
        • 12.3.5.1.1. By Value
      • 12.3.5.2. Market Share & Forecast
        • 12.3.5.2.1. By Endometriosis Type
        • 12.3.5.2.2. By Diagnostic Method
        • 12.3.5.2.3. By Therapeutic Method
        • 12.3.5.2.4. By Distribution Channel
        • 12.3.5.2.5. By End User

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape

  • 15.1. Abbott Laboratories, Inc.
  • 15.2. AbbVie, Inc.
  • 15.3. Bayer AG
  • 15.4. Pfizer, Inc.
  • 15.5. Ipsen SA
  • 15.6. Evotec SE
  • 15.7. Myovant Sciences Ltd.
  • 15.8. Philogen S.p.A.
  • 15.9. Astellas Pharma Inc.
  • 15.10. Orphagen Pharmaceuticals, Inc.

16. Strategic Recommendations